Avience Biomedicals IPO Listing Preview: Listing on NSE SME with Rs 58 to Rs 60 GMP

Avience Biomedicals IPO listing on NSE SME. GMP Rs 58-60 (+27.9%). Price Rs 196-208. Lot 1,200 shares. Min investment Rs 2,49,600. Allotment June 23.

The Avience Biomedicals IPO listing is scheduled for on NSE SME, with a nil GMP indicating the grey market expects a flat listing near the issue price. The Avience Biomedicals IPO listing follows the close of subscription on June 22, 2026, during which the company raised Rs 30.24 crore at a price band of Rs 196 to Rs 208 per share. The Avience Biomedicals IPO listing will be closely watched by retail investors who applied during the June 18 to June 22 subscription window, with the allotment having been finalised on June 23, 2026. The grey market premium heading into the Avience Biomedicals IPO listing day provides one informal signal, but the actual listing price will be determined by real market demand.

Avience Biomedicals is a ISO-certified manufacturer, supplier and exporter of molecular diagnostic solutions, IVD rapid test kits, serology products, biochemistry analysers, and viral transport media, operating from Noida, Uttar Pradesh. The company’s financials indicate Revenue FY25: Rs 45.97 crore (+88.6% YoY). Net Profit FY25: Rs 7.23 crore (+237% YoY). P/E: 16.56x, EPS Rs 12.56, RoNW 22.38%. Anchor: Rs 8.52 crore from 4 institutions.. Kunal Singla, Associate Director at Univest notes that investors should track the Avience Biomedicals IPO listing performance in real time on through the exchange platform and not rely solely on GMP levels, as grey market premiums are unofficial and can differ significantly from actual listing prices for NSE SME issues.

Click Here – Get Free Investment Predictions

Avience Biomedicals IPO Listing Preview: Key Data

The Avience Biomedicals IPO listing is occurring in a market environment where the Nifty 50 is at 24,156 (+0.60%) on June 22, 2026. A positive broad market backdrop typically supports IPO listing performance. Investors who have been allotted shares should track the opening price on June 25, 2026 relative to the issue price to assess listing day momentum. For NSE SME listings, the first 30 minutes of trading often establish the price direction for the rest of the day.

The Avience Biomedicals IPO listing price will ultimately reflect whether market participants at large endorse the valuation implied by the issue price. Investors with a longer holding period should evaluate the company’s business fundamentals rather than making decisions based solely on the listing day move. Post-listing performance is determined by earnings growth, sector tailwinds, and broader market conditions over weeks and months rather than just the Avience Biomedicals IPO listing day price action.

What to Watch on Avience Biomedicals IPO Listing Day

Investors tracking the Avience Biomedicals IPO listing on June 25, 2026 should monitor opening trade price versus issue price, trading volumes, and sector context. Use the Univest Screener for live NSE SME listing data.

Track Avience Biomedicals IPO Listing Live on Univest Screener

1. Opening Price vs Issue Price

The most immediate signal on the Avience Biomedicals IPO listing day will be the opening trade price on NSE SME relative to the issue price. A flat opening near the issue price would confirm the nil GMP expectation. However, the Avience Biomedicals IPO listing price is subject to immediate supply-demand dynamics on the day, which can differ from grey market sentiment.

2. Trading Volume and Market Depth

For SME listings, trading volume on the Avience Biomedicals IPO listing day reflects the depth of investor interest. High volume supports efficient price discovery, while thin volumes can lead to wider bid-ask spreads. Investors planning to exit on the Avience Biomedicals IPO listing day should place limit orders rather than market orders, particularly in the first hour of trading when spreads may be wider.

3. Post-Listing Fundamental Outlook

Beyond the Avience Biomedicals IPO listing day, investors with a medium to long-term view should evaluate the company’s revenue growth trajectory, profitability improvements, and sector positioning. The listing price is one data point; the long-term investment case rests on the company’s ability to compound earnings in the years after listing. Consult a SEBI-registered financial advisor before making decisions based on Avience Biomedicals IPO listing day performance.

Conclusion

The Avience Biomedicals IPO listing on June 25, 2026 on NSE SME is supported by a nil GMP indicating the grey market expects a flat listing near the issue price. Allotted investors should track the Avience Biomedicals IPO listing in real time and evaluate exit or holding decisions based on both listing day performance and longer-term business fundamentals. GMP is unofficial and the actual Avience Biomedicals IPO listing price may differ. Consult a SEBI-registered advisor before making investment decisions.

Download the Univest iOS App or Univest Android App to track the Avience Biomedicals IPO listing live and access stock research on Univest.

Frequently Asked Questions

What is the Avience Biomedicals IPO listing date?

Ans. The this listing date is June 25, 2026 on NSE SME. The IPO subscribed from June 18 to June 22, 2026. Allotment was finalised on June 23, 2026. Shares will be credited to demat accounts before the the IPO listing on June 25, 2026.

What is the Avience Biomedicals IPO GMP today?

Ans. The Avience Biomedicals IPO GMP as of June 22, 2026 is Rs 58 to Rs 60 (+27.9%), implying an expected listing price of Rs 266 (approx. +28%). GMP is unofficial and unregulated and does not guarantee actual listing performance.

What is the expected Avience Biomedicals IPO listing price?

Ans. Based on the Avience Biomedicals IPO GMP of Rs 58 to Rs 60 as of June 22, the indicative expected listing price is Rs 266 (approx. +28%). However, actual listing price may differ significantly depending on market conditions on June 25, 2026 on NSE SME.

How to check Avience Biomedicals IPO allotment status?

Ans. The Avience Biomedicals IPO allotment was finalised on June 23, 2026. Investors can check allotment status on the registrar Skyline Financial Services Private Limited website or the BSE/NSE websites by entering PAN, application number, or DP/Client ID. Shares for allotted applicants will be credited before the the listing on June 25, 2026.

What does Avience Biomedicals do?

Ans. Avience Biomedicals is a ISO-certified manufacturer, supplier and exporter of molecular diagnostic solutions, IVD rapid test kits, serology products, biochemistry analysers, and viral transport media, operating from Noida, Uttar Pradesh. The company is now listed on NSE SME following its IPO at a price band of Rs 196 to Rs 208 per share.

What are the financial highlights of Avience Biomedicals?

Ans. Revenue FY25: Rs 45.97 crore (+88.6% YoY). Net Profit FY25: Rs 7.23 crore (+237% YoY). P/E: 16.56x, EPS Rs 12.56, RoNW 22.38%. Anchor: Rs 8.52 crore from 4 institutions. Investors should review the full financial disclosures in the company’s prospectus on BSE and NSE before making investment decisions.

Can I sell Avience Biomedicals shares on listing day?

Ans. Yes, investors who received allotment can sell shares on the listing date of June 25, 2026 on NSE SME. Selling on listing day is a personal decision. Consult a SEBI-registered financial advisor before making post-listing decisions.

What is the lot size for Avience Biomedicals IPO?

Ans. The Avience Biomedicals IPO lot size is 600 shares. The minimum investment at the upper price band is Rs 2,49,600 (2 lots = 1,200 shares). Shares will be in demat accounts by June 23, 2026 ahead of the June 25, 2026 listing on NSE SME.